

DAFTAR PUSTAKA

1. Bruunsgaard H, Pedersen BK: Age-related inflammatory cytokines and disease. *Immunol Allergy Clin North Am* 2003, 23:15-39
2. Darmawan A, Santosa S. Gambaran Kepadatan Tulang Wanita Menopause Pada Kelompok 'X' di Bandung. Vol. 2, No. 1, Juli 2002: 1-7
3. Dijkstra, NM and Papapoulos, SE. 2016. Sclerostin Inhibition in the Management of Osteoporosis. *Calcif Tissue Int.* 98:370–380 DOI 10.1007/s00223-016-0126-6
4. Kawiya I. Osteoporosis Patogenesis Diagnosis Dan Penanganan Terkini. Volume 10 158 Nomor 2 Mei 2009: 157-170
5. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J, Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A, Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C. 2009. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. *J Bone Miner Res* 24:578–588
6. Li X, Ominsky MS, Warmington KS, Niu QT, Asuncion FJ, Barrero M, Dwyer D, Grisanti M, Stolina M, Kostenuik PJ, Simonet WS, Paszty C, Ke HZ. 2011. Increased bone formation and bone mass induced by sclerostin antibody is not affected by pretreatment or cotreatment with alendronate in osteopenic, ovariectomized rats. *Endocrinology* 152:3312–3322
7. Li X, Niu QT, Warmington KS, Asuncion FJ, Dwyer D, Grisanti M, Han CY, Stolina M, Eschenberg MJ, Kostenuik PJ, Simonet WS, Ominsky MS, Ke HZ. 2014. Progressive increases in bone mass and bone strength in

- an ovariectomized rat model of osteoporosis after 26 weeks of treatment with a sclerostin antibody. *Endocrinology* 155:4785–4797
8. McNabb, C; Patton, D; Hayes, JS. 2016. Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges. Hindawi Publishing Corporation *Journal of Osteoporosis* Volume 2016, Article ID 6217286, 22 pages <http://dx.doi.org/10.1155/2016/6217286>
 9. Mescher A.L., 2013 *Junqueira's Basic Histology Text and Atlas*, 13th Edition, McGraw-Hill Education, USA, p. 239-246.
 10. Minropa A. Faktor-Faktor Yang Berhubungan Dengan Resiko Osteoporosis Pada Lansia Di Kenagarian Api-Api Wilayah Kerja Puskesmas Pasar Baru Kecamatan Bayang Kabupaten Pesisir Selatan Tahun 2013. 2013
 11. Ominski MS, Varela A, Smith SY, Jolette J, Lesage E, Buntich S, Boyce RW. 2015. Romosozumab (sclerostin antibody) improves bone mass and strength in ovariectomized cynomolgous monkeys after 12 months of treatment. *J Bone Miner Res* 30(Suppl 1):S6
 12. Petrovsky N, Aguilar J.C: Vaccine adjuvants: Current state and future trends *Immunology and Cell Biology* (2004) 82, 488–496
 13. Setyorini A, Suandi IKG, Sidiartha I, Suryawan W. Pencegahan Osteoporosis dengan Suplementasi Kalsium dan Vitamin D pada Penggunaan Kortikosteroid Jangka Panjang. Vol. 11, No. 1, Juni 2009: 32-38
 14. Silverman S. Review Article Sclerostin. Vol.2010 16 February 2010: 1-3
 15. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie M.T, Martin T.J. 1999. Modulation of Osteoclast Differentiation and Function by the New

Members of the Tumor Necrosis Factor Receptor and Ligand Families
 Endocrine Reviews 20 (3): 345-357

16. Syam Y, Noersasongko D, Sunaryo H. Fraktur Akibat Osteoporosis. Vol. 2, Nomor 2, Juli 2014
17. Susanti N. Vaksinasi Lansia Upaya Preventif Meningkatkan Imunitas Akibat Proses Penuaan. El-Hayah Vol. 4, No.2 Maret 2014: 75-80
18. Wratsangka R. Pemberian Terapi Sulih Hormon Sebagai Upaya Meningkatkan Kesehatan Wanita Menopause. Vol. 18, No.3 1999: 155-162
19. Yavropoulou M, Xygonakis C, Lolou M, et al. The sclerostin story: From human genetics to the development of novel anabolic treatment for osteoporosis. 2014: 476-487
20. Yun AJ, Lee PY: Maladaptation of the link between inflammation and boneturnover may be a key determinant of osteoporosis. Med Hypotheses 2004,63:532-537

